EAPI Share Price Performance
€1.26
-1.60 (-55.84%)
25.6% undervalued intrinsic discount
€1.70
Fair Value
Price €1.26
AnalystHighTarget €1.70
AnalystConsensusTarget €1.48
AnalystLowTarget €1.00
Fair Value€1.70
Share Pricen/a
Narrative Update • Jul 14
Euroapi S.A. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
EAPI Community Narratives
AN
Fair Value
·Fair Value €1.7 25.6% undervalued intrinsic discount
Green Chemistry And Domestic Sourcing Will Unlock Secular Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value €1.48 14.3% undervalued intrinsic discount
Capacity Expansion And Biotechnological Processes Will Strengthen API Supply
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value €1 26.4% overvalued intrinsic discount
Rising Regulatory And Geopolitical Risks Will Undermine API Profits
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Green Chemistry And Domestic Sourcing Will Unlock Secular Demand
Euroapi looks like it could benefit as drugmakers push to make more ingredients closer to home and choose cleaner manufacturing methods, with new technology and government support helping it rebuild profitability. But it still leans heavily on a few big customers and faces tough pricing pressure, which could limit how much of that upside actually shows up in results.Read more
AN
€1.7
25.6% undervalued intrinsic discount
Fair Value
Profit Margin
2.38%
Future PE
9.9x
Price in 2029
€2.05
Capacity Expansion And Biotechnological Processes Will Strengthen API Supply
Euroapi is trying to rebuild its drug-ingredient business by expanding production, investing in new biotech-style manufacturing, and shifting toward higher-value work for big pharmaceutical customers. The upside is a steadier, more profitable mix, but intense low-cost competition, heavy reliance on a few customers, and the strain of a major restructuring could derail the turnaround.Read more
AN
€1.48
14.3% undervalued intrinsic discount
Fair Value
Profit Margin
0.73%
Future PE
28.73x
Price in 2029
€1.78
Rising Regulatory And Geopolitical Risks Will Undermine API Profits
Euroapi makes key ingredients used in many medicines, but growing red tape and a world that’s turning more inward could make it harder to sell profitably across borders. The bigger question is whether its push into more specialized products and efficiency gains can offset pressure from big customers, price wars, and shifting drug technology.Read more
AN
€1
26.4% overvalued intrinsic discount
Fair Value
Profit Margin
0.24%
Future PE
61.68x
Price in 2029
€1.21
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
EAPI: Execution On Efficiency Plans Could Unlock Upside Under Reset Expectations
Fair Value: €1.7 25.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EAPI: Reset Expectations And Higher Future P/E Could Support Rebound
Fair Value: €1.48 14.3% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EAPI: Revenue Contraction And Margin Pressure Will Continue To Restrain Future Earnings
Fair Value: €1 26.4% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Euroapi S.A. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Jul 29, 2026
- -2.22
- 17.00%
- -24.77%
- 5.8%
About EAPI
- Founded
- 2020
- Employees
- 2961
- CEO
- WebsiteView website
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; and steroids and hormones substances. It also provides API solutions, such as vitamin B12, prostaglandins, corticoids and hormones, anti-infectives, opiates and controlled substances, small and complex molecules, and intermediates and reagents. It sells their products to laboratories in the pharmaceutical industry, manufacturers of generic drug and animal health products, consumer health companies, nutrition companies, cosmetics companies, biotechnology companies, contract development and manufacturing organizations. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.
Recent EAPI News & Updates
Narrative Update • Jun 30
EAPI: Reset Expectations And Higher Future P/E Could Support Rebound
Analysts have reduced their fair value estimate for Euroapi, cutting the price target from €2.00 to about €1.48. This is broadly in line with a recent move by the Street to bring targets down toward €1.70 as they factor in weaker revenue growth expectations and revised profitability assumptions alongside a higher future P/E multiple.
Narrative Update • Jun 16
